Maria‐Theresa Krauth

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Vaccination with genetically engineered allergens prevents progression of allergic disease

Verena Niederberger, Friedrich Horak, Susanne Vrtala et al. · Proceedings of the National Academy of Sciences · 2004 · 377 citations · Full text

Life Sciences, Biotechnology, Immunology +17

Allergen‐specific immunotherapy with a monophosphoryl lipid A‐adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy‐induced blocking antibodies

Nadine Mothes, M. Heinzkill, K. J. Drachenberg et al. · Clinical & Experimental Allergy · 2003 · 267 citations

Life Sciences, Immunology, Pharmacology +16

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Karl J. Aichberger, Matthias Mayerhofer, Maria‐Theresa Krauth et al. · Blood · 2004 · 252 citations · Full text

Medicine, Molecular Biology, Oncology +12

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Edit Porpaczy, Sabrina Tripolt, Andrea Hoelbl‐Kovacic et al. · Blood · 2018 · 154 citations · Full text

Medicine, Hematology, Immunology +14